

U.S. NUCLEAR REGULATORY COMMISSION

Amendment No. 16

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p>Licensee</p> <p>1. Ashford Presbyterian Community Hospital Nuclear Medicine and Cardiovascular Laboratory</p> <p>2. P.O. Box 9020032 San Juan, Puerto Rico 00902-0032</p>	<p>In accordance with the letter dated March 21, 2016,</p> <p>3. License number 52-11810-02 is amended in its entirety to read as follows:</p> <hr/> <p>4. Expiration date December 31, 2021</p> <hr/> <p>5. Docket No. 03009858 Reference No.</p>
--	--

- | | | |
|---|--|--|
| 6. Byproduct, source, and/or special nuclear material | 7. Chemical and/or physical form | 8. Maximum amount that licensee may possess at any one time under this license |
| A. Any byproduct material permitted by 10 CFR 35.100 | A. Any | A. As needed |
| B. Any byproduct material permitted by 10 CFR 35.200 | B. Any | B. As needed |
| C. Any byproduct material permitted by 10 CFR 35.300 | C. Any | C. 1.1 curies |
| D. Iodine 125 permitted by 10 CFR 35.400 | D. Sealed Sources [IsoAid, L.L.C. Model IAI-125A; Core Oncology, Inc. (formerly Mills Biopharmaceuticals, LLC) Model I-125 SL; Bard Brachytherapy, Inc. Model STM-1251; Theragenics Corp. I-seed Models 125.S06 and AgX100; Medipysics, Inc. Model 6711] | D. 3.5 curies |

9. Authorized use:

- A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
- B. Any imaging and localization study permitted by 10 CFR 35.200.
- C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.
- D. Any manual brachytherapy procedure permitted by 10 CFR 35.400, for which the patient can be released under the provisions of 10 CFR 35.75.

CONDITIONS

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
52-11810-02Docket or Reference Number
03009858

Amendment No. 16

10. Licensed material may be used or stored only at the licensee's facilities located at 1st, 2nd, and 3rd Floors, 1451 Ashford Avenue, San Juan, Puerto Rico.
11. The Radiation Safety Officer for this license is David Rhoe.
12. Licensed material is only authorized for use by, or under the supervision of:
- A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.
- B. The following individuals are authorized users for medical use as indicated:
- | <u>Authorized Users</u> | <u>Material and Use</u> |
|---------------------------------|---|
| Carlos E. Jiménez, M.D. | 35.100; 35.200; 35.300 |
| Bartolo Santiago-Delgado, M.D. | 35.100; 35.200; 35.300 |
| Roberto A. Annexy-Márquez, M.D. | 35.100; 35.200; Oral administration of sodium iodide Iodine-131 |
| Carlos Remedios, M.D. | 35.400 |
13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.
14. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
52-11810-02Docket or Reference Number
03009858

Amendment No. 16

15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

- | | | |
|----|---|---------------|
| A. | Application dated June 29, 2011 | [ML111870423] |
| B. | Letter dated December 19, 2011 | [ML113550118] |
| C. | Letter dated December 22, 2014 | [ML15012A408] |
| D. | Letter dated December 1, 2015 | [ML15350A164] |
| E. | Facility diagram dated January 14, 2016 | [ML16027A050] |
| F. | Letter dated March 21, 2016 | [ML16102A365] |
| G. | Facility diagram dated May 17, 2016 | [ML16147A449] |



For the U.S. Nuclear Regulatory Commission

Date May 27, 2016

By

Original signed by Shawn Seeley

Shawn Seeley
Medical Branch
Division of Nuclear Materials Safety
Region I
King of Prussia, Pennsylvania 19406